Inflammation-targeted therapies and cancer - 05/06/21
pages | 13 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Data are reassuring regarding the overall risk of cancer with TNF inhibitors (TNFi). |
• | The risk of lymphoma does not seem to be increased with TNFi. |
• | There is probably an increased risk of non-melanoma skin cancer (NMSC) associated with TNFi, as with other immunosuppressants. |
• | There is no signal for an increased risk of cancer with other biological DMARDs, but additional data are needed. |
• | A recent post-marketing surveillance study found out an increased risk of malignancies for tofacitinib compared with TNFi; additional data are therefore urgently needed to confirm or not these results. |
Abstract |
Objective |
To review and analyze the current knowledge on the risk of malignancy associated with inflammation-targeted therapies in rheumatic diseases.
Methods |
We performed a non-systematic literature review on PubMEd MEDLINE by screening randomized controlled trials, meta-analyses, reviews, and observational studies focusing on malignancies and inflammation-targeted therapies including TNF inhibitors, other biologics and JAK inhibitors in rheumatic diseases.
Results |
Data from literature are reassuring regarding the overall risk of incident and recurrent cancer with TNF inhibitors. The risk of lymphoma is more difficult to analyze and data are controversial; however, in most of the studies, this risk does not seem to be significanlty increased. By contrast, there is probably an increased risk of non-melanoma skin cancer associated with TNF inhibitors, as with other immunosuppressants. There is no signal for an increased risk of malignancies with other biological DMARDs, but additional data are needed. A recent post-marketing surveillance study found out an increased risk of malignancies for tofacitinib compared with TNFi; additional data are, therefore, urgently needed to confirm or not these results.
Conclusion |
Data are presently reassuring regarding the overall risk of cancer, whatever the inflammation-targeted treatment. However, additional data are needed for non-TNF biologics and JAK-inhibitors.
Le texte complet de cet article est disponible en PDF.Keywords : Cancer, Rheumatic diseases, Biologics, Targeted synthetic DMARDs
Plan
Vol 88 - N° 4
Article 105176- juillet 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?